Arlynn Mulne: Update on pediatric oncology - El Paso Times
Today, almost 75 percent of childhood cancer patients will be cured of their disease. This progress has come through years of coordinated efforts among physicians treating pediatric cancer patients and researchers in the fields of cancer biology and therapeutics.
...
Dr. Arlynn Mulne is an associate professor in the Department of Pediatrics at Texas Tech University Health Sciences Center at El Paso. She is also chief of the pediatric hematology/oncology section.
Read the full story >>
Related Stories
TTUHSC School of Nursing to Celebrate New YWCA Location
Community members in central Lubbock now have access to health care services and prenatal programs at one location inside the YWCA.
A Rite of Passage for Next Generation of Physicians
Students in TTUHSC's School of Medicine Class of 2028 received their first white coat and pledged their commitment to the medical profession at the White Coat Ceremony Friday (July 26) at the Buddy Holly Hall of Performing Arts and Sciences.
How Does Your Garden Grow?
As spring approaches, some people’s thoughts turn to gardening. Whether it’s a flower garden they desire or a vegetable garden want to have, they begin planning what they’ll plant and what they need to do to ensure a successful garden.
Recent Stories
Alumni Spotlight: Sister Duo Offers Local, Personalized Allied Health Services
Abagale (Abby) Chapman, OT (2014), and Hannah Cowden, SLP (2017), are sisters working together to help children in Lubbock and the surrounding areas become the greatest version of themselves.
TTUHSC Faculty Receive Chancellor’s Council Distinguished Teaching and Research Awards
Recognizing academic excellence, the honors are the most prestigious awards granted to faculty throughout the TTU System.
TTUHSC Researchers Developing Lupus Treatment
Jon McCord, Ph.D., a recent postdoc at the TTUHSC School of Medicine, and Bryan Sutton, Ph.D., from TTUHSC’s Department of Cell Physiology and Molecular Biophysics, study a mutation in a specific protein found in lupus patients. Together, they aim to become the force behind this new, patent pending therapy.